loading
Moonlake Immunotherapeutics stock is traded at $40.74, with a volume of 63,231. It is down -2.25% in the last 24 hours and down -6.48% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$41.76
Open:
$41.75
24h Volume:
63,231
Relative Volume:
0.20
Market Cap:
$2.61B
Revenue:
-
Net Income/Loss:
$-80.77M
P/E Ratio:
-32.08
EPS:
-1.27
Net Cash Flow:
$-80.80M
1W Performance:
-0.34%
1M Performance:
-6.48%
6M Performance:
-11.85%
1Y Performance:
-19.84%
1-Day Range:
Value
$40.32
$42.51
1-Week Range:
Value
$39.87
$43.41
52-Week Range:
Value
$37.55
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Name
Moonlake Immunotherapeutics
Name
Phone
41 41 510 8022
Name
Address
DORFSTRASSE 29, ZUG
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
40.72 2.61B 0 -80.77M -80.80M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.74 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
690.74 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
636.58 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.51 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
113.14 27.34B 3.30B -501.07M 1.03B -2.1146

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-17-25 Upgrade Goldman Neutral → Buy
Nov-05-24 Resumed Wedbush Outperform
Aug-26-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-25-24 Initiated Oppenheimer Outperform
Apr-02-24 Initiated Goldman Neutral
Feb-15-24 Initiated Wolfe Research Outperform
Dec-08-23 Initiated Citigroup Buy
Nov-02-23 Initiated Stifel Buy
Sep-14-23 Downgrade Bryan Garnier Buy → Neutral
Aug-31-23 Initiated Needham Buy
Jun-15-23 Initiated Barclays Equal Weight
May-01-23 Initiated Guggenheim Buy
Mar-22-23 Initiated Wedbush Outperform
Mar-09-23 Initiated BTIG Research Buy
Feb-14-23 Initiated Cantor Fitzgerald Overweight
Feb-02-23 Initiated Bryan Garnier Buy
Nov-11-22 Initiated Jefferies Buy
Aug-25-22 Initiated SVB Leerink Outperform
Jul-21-22 Initiated H.C. Wainwright Buy
Jul-07-22 Initiated Cowen Outperform
View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

pulisher
Mar 02, 2025

The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 28, 2025
pulisher
Feb 28, 2025

The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 25, 2025

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey

Feb 25, 2025
pulisher
Feb 24, 2025

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St

Feb 24, 2025
pulisher
Feb 23, 2025

Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA

Feb 23, 2025
pulisher
Feb 23, 2025

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey

Feb 23, 2025
pulisher
Feb 22, 2025

10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey

Feb 22, 2025
pulisher
Feb 21, 2025

Congress Asset Management Co. Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

Rice Hall James & Associates LLC Raises Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Will MoonLake Immunotherapeutics Lead Healthcare Stocks’ Resurgence? - DSA

Feb 20, 2025
pulisher
Feb 20, 2025

Why MoonLake Immunotherapeutics Could Be the Next Big Bet in Healthcare - MotoPaddock

Feb 20, 2025
pulisher
Feb 20, 2025

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 20, 2025
pulisher
Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025
pulisher
Feb 18, 2025

(MLTX) Proactive Strategies - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 13, 2025

What is Leerink Partnrs' Forecast for MLTX FY2025 Earnings? - MarketBeat

Feb 13, 2025
pulisher
Feb 11, 2025

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely - Yahoo Finance

Feb 11, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

JPMorgan Chase & Co. Has $62,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

(MLTX) Trading Report - Stock Traders Daily

Feb 07, 2025
pulisher
Feb 06, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Feb 06, 2025
pulisher
Feb 04, 2025

JPMorgan Chase & Co. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Feb 04, 2025
pulisher
Jan 30, 2025

Swiss company MoonLake leverages Cambridge in transformative year - Business Weekly

Jan 30, 2025
pulisher
Jan 27, 2025

When the Price of (MLTX) Talks, People Listen - Stock Traders Daily

Jan 27, 2025
pulisher
Jan 24, 2025

Cantor Fitzgerald Estimates MLTX FY2025 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Weighs in on MLTX FY2025 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 21, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 6.3%Still a Buy? - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media

Jan 20, 2025

Moonlake Immunotherapeutics Stock (MLTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Moonlake Immunotherapeutics Stock (MLTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Sturge Simon
Director
Oct 04 '24
Sale
53.72
171,000
9,186,120
171,980
$78.98
price down icon 2.93%
$23.11
price up icon 1.81%
$34.05
price up icon 1.25%
$20.27
price down icon 2.22%
biotechnology ONC
$245.74
price down icon 9.54%
$113.54
price up icon 0.48%
Cap:     |  Volume (24h):